Psilocybin
Compass Pathways Lands $125M Investment
If all warrants are exercised, an additional $160 million comes into play.
The post Compass Pathways Lands $125M Investment appeared first on Green Market…
Biotech firm Compass Pathways plc (Nasdaq: CMPS) is set to receive a $125 million investment, with potential for an additional $160 million, in a deal with health care investors TCGX and Aisling Capital, the company announced Wednesday.
The company will sell more than 16 million shares (specifically, American Depositary Shares or ADS) at roughly $7.78 each. Along with those shares, investors will receive warrants priced at $9.93 each, valid for three years. If all warrants are exercised, the added $160 million comes into play.
Because there’s a limit to how many shares an investor can own – with the cap is set at 9.99% – a range of investment firms, including Vivo Capital, RA Capital, and Surveyor Capital, have pitched in. The financing is expected to close on Friday.
Compass CEO Kabir Nath views the investment as a nod to the potential of psychedelic medicine, especially psilocybin, in treating conditions like treatment-resistant depression, PTSD, and anorexia nervosa.
“We thank these investors for their confidence in our rigorous approach to building a strong base of evidence for the potential of COMP360 psilocybin treatment to help people,” Nath said in a statement.
The funds are anticipated to extend the company’s operations runway until late 2025, pushing along core research and commercial efforts.
Morgan Stanley and TD Cowen are facilitating the financial transaction, with both set to receive a combined fee of roughly 6% of the gross proceeds, according to filings.
The post Compass Pathways Lands $125M Investment appeared first on Green Market Report.
psilocybin psychedelic depression ptsd investors financing shares nasdaq deal capital compass research
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
GH Research advances depression therapies, burns cash
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
-
Psychedelics1 week agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics1 week agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Law & Regulation1 week ago
Tryp Therapeutics, Exopharm merger approved by shareholders
-
Psychedelics1 week ago
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
-
Law & Regulation1 week ago
Adastra reports record sales in 2023, but remains in the red
-
LSD1 week agoThe First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Psilocybin7 days agoPsychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
